Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination therapy of melanoma using kinase inhibitors.

Current opinion in oncology - 1 Mar 2015

Heppt Markus V, Tietze Julia K, Graf Saskia A, Berking Carola

Abstract excerpt

PURPOSE OF REVIEW: Treatment options for metastatic melanoma depend on the clinical course of the disease and the molecular profile such as mutations of the BRAF gene. In this article, we review the current state of targeted therapy with kinase inhibitors. RECENT FINDINGS: Despite major advancements in targeted therapy of metastatic melanoma, most patients relapse and show progressive disease after 5-7 months...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to MAP Kinase Signaling System

Share to Melanoma, Cutaneous Malignant

Share to Mitogen-Activated Protein Kinases

Share to Neoplasm Recurrence, Local

Share to Skin Neoplasms

Source

Identifiers

PMID: 25602684
DOI: 10.1097/CCO.0000000000000160

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination therapy of melanoma using kinase inhibitors.PMID 25602684Read ↗

Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.Semantic proximity Read ↗

Integrating BRAF/MEK inhibitors into combination therapy for melanomaSemantic proximity Read ↗

BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.Semantic proximity Read ↗

BRAF inhibitors: resistance and the promise of combination treatments for melanomaSemantic proximity Read ↗

BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma.Semantic proximity Read ↗

Combination therapy of BRAF inhibitors for advanced melanoma with BRAF V600 mutation: a systematic review and meta-analysis.Semantic proximity Read ↗

Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.Semantic proximity Read ↗

Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.Semantic proximity Read ↗

Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.Semantic proximity Read ↗

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read ↗

Overcoming resistance to BRAF inhibitorsSemantic proximity Read ↗

Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.